Simian Immunodeficiency Virus Diversity and Pathogenesis

A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Animal Viruses".

Deadline for manuscript submissions: closed (15 September 2021) | Viewed by 8368

Special Issue Editor


E-Mail Website
Guest Editor
Division of Infectious Diseases, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
Interests: SIV; pathogenesis

Special Issue Information

Dear Colleagues,

Simian immunodeficiency virus (SIV)-infected macaques are the most widely used animal model in AIDS research. This is one of the best animal models in the history of infection diseases, as it reproduces in a condensed time frame all the major pathogenic characteristics of human immunodeficiency virus (HIV) infection. HIV and SIV also share molecular biology features, including target cells, mechanisms of cell infection, and key features of virus persistence. The use of animal models has permitted the definition of all the key features of HIV infection that impact the strategies of viral control. In fact: (a) the study of the early events of SIV infection at the mucosal sites of entry allowed the identification of strategies aimed at controlling viral transmission; (b) detailed studies of virus replication and CD4+ T cell depletion permitted us to understand the mechanisms of HIV pathogenesis and were instrumental for establishing new therapeutic guidelines; (c) the studies of reservoir seeding, maintenance, and reactivation performed in macaques were instrumental for defining cure strategies; (d) the detailed assessment of immune responses and the correlates of immune protection placed the macaque model at the center of AIDS vaccine research; (e) finally, more recently, comparative studies in pathogenic and nonpathogenic nonhuman primate models of AIDS established the critical role of chronic inflammation and immune activation in disease progression and death, leading to a better understanding of the mechanisms of and prevention measures for HIV-related comorbidities. Also, a detailed characterization of SIV diversity in their natural hosts allowed us to trace the origin of HIV in monkeys and apes. In most of these cases, studies in monkeys preceded the human studies by decades and clearly piloted the field. More recently, significant achievements in generating new more natural viral strains for use in nonhuman primates and better antiretroviral treatment regimens reinvigorated the SIV/macaque model and opened new avenues for its use in major areas of current HIV research. These achievements have considerably shaped the field of research based on animal models; not surprisingly, this research model is used to study other infectious diseases, particularly, emergent infections such as that by SARS-CoV-2. This Special Issue will present key achievements in the field of SIV infection of nonhuman primates and model contributions to the study of HIV pathogenesis, prevention, treatment, and cure.

Prof. Cristian Apetrei
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

67 pages, 3971 KiB  
Review
So Pathogenic or So What?—A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research
by Adam J. Kleinman, Ivona Pandrea and Cristian Apetrei
Viruses 2022, 14(1), 135; https://doi.org/10.3390/v14010135 - 12 Jan 2022
Cited by 4 | Viewed by 4067
Abstract
HIV infection requires lifelong antiretroviral therapy (ART) to control disease progression. Although ART has greatly extended the life expectancy of persons living with HIV (PWH), PWH nonetheless suffer from an increase in AIDS-related and non-AIDS related comorbidities resulting from HIV pathogenesis. Thus, an [...] Read more.
HIV infection requires lifelong antiretroviral therapy (ART) to control disease progression. Although ART has greatly extended the life expectancy of persons living with HIV (PWH), PWH nonetheless suffer from an increase in AIDS-related and non-AIDS related comorbidities resulting from HIV pathogenesis. Thus, an HIV cure is imperative to improve the quality of life of PWH. In this review, we discuss the origins of various SIV strains utilized in cure and comorbidity research as well as their respective animal species used. We briefly detail the life cycle of HIV and describe the pathogenesis of HIV/SIV and the integral role of chronic immune activation and inflammation on disease progression and comorbidities, with comparisons between pathogenic infections and nonpathogenic infections that occur in natural hosts of SIVs. We further discuss the various HIV cure strategies being explored with an emphasis on immunological therapies and “shock and kill”. Full article
(This article belongs to the Special Issue Simian Immunodeficiency Virus Diversity and Pathogenesis)
Show Figures

Figure 1

17 pages, 517 KiB  
Review
Therapeutic Potential of IL-15 and N-803 in HIV/SIV Infection
by Olivia Harwood and Shelby O’Connor
Viruses 2021, 13(9), 1750; https://doi.org/10.3390/v13091750 - 02 Sep 2021
Cited by 17 | Viewed by 3282
Abstract
IL-15, a proinflammatory cytokine critical for the generation, maintenance, and homeostasis of T cell responses, is produced naturally in response to HIV/SIV infection, but has also demonstrated therapeutic potential. IL-15 can boost CD4+ and CD8+ T cell and NK cell proliferation, [...] Read more.
IL-15, a proinflammatory cytokine critical for the generation, maintenance, and homeostasis of T cell responses, is produced naturally in response to HIV/SIV infection, but has also demonstrated therapeutic potential. IL-15 can boost CD4+ and CD8+ T cell and NK cell proliferation, activation, and function. However, IL-15 treatment may cause aberrant immune activation and accelerated disease progression in certain circumstances. Moreover, the relationship between the timing of IL-15 administration and disease progression remains unclear. The IL-15 superagonist N-803 was developed to expand the therapeutic potential of IL-15 by maximizing its tissue distribution and half-life. N-803 has garnered enthusiasm recently as a way to enhance the innate and cellular immune responses to HIV/SIV by improving CD8+ T cell recognition and killing of virus-infected cells and directing immune cells to mucosal sites and lymph nodes, the primary sites of virus replication. N-803 has also been evaluated in “shock and kill” strategies due to its potential to reverse latency (shock) and enhance antiviral immunity (kill). This review examines the current literature about the effects of IL-15 and N-803 on innate and cellular immunity, viral burden, and latency reversal in the context of HIV/SIV, and their therapeutic potential both alone and combined with additional interventions such as antiretroviral therapy (ART) and vaccination. Full article
(This article belongs to the Special Issue Simian Immunodeficiency Virus Diversity and Pathogenesis)
Back to TopTop